Latest SNPX Press Release
“How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.”
— Robert G. Allen
Jeff Bishop
Sally O’Malley would be a MyMD superfan
Sponsored by: Hey guys and gals, If you have been watching or trading MYMD the last few weeks, it has been a painful reminder that high-flying stocks can also come back down just as quickly. The good news is that MYMD is trading back at key support levels not...
MYMD Provides Dosing Update on Phase 2 Multi-Center Clinical Trial
Latest MYMD Press Release
Betting on SNPX
Sponsored By Hello again, Trader! Yes, I’ve been talking a lot about Synaptogenix (SNPX) lately, and yes, I know the trading has been disappointing to say the least the last few days. In times like this when the market tests...
This Biotech company caught my eye
Sponsored by: If you’ve been following our updates, you know that MYMD-1® seeks to target the CAUSE, not just the symptoms, that drive autoimmunity and inflammation. However, did you also know that MYMD-1® may behave like an ANTIDEPRESSANT? This...
RYSE and Shine!
Sponsored By: Want to invest in the next big brand name in your home and get in on the ground floor of an innovative technology company? Meet RYSE. RYSE is the first retrofit solution to motorize and automate installed window blinds and shades,...
Could a cure be around the corner 🤔
Sponsored By Do you know someone suffering from Alzheimer’s or has lost their fight with it? It’s likely you do, as 1 in 3 seniors dies with Alzheimer's (AD) or another dementia -- which kill more than breast cancer and...
MyMD battling brain-related disorders – let’s gooooo
Sponsored By Recently we’ve been following the story of MyMD, particularly in regard to its lead drug indication – MYMD-1® – in Phase 2 trials for sarcopenia (aka aging). But what led MyMD to pursue this path? As all companies have limited resources,...
Injection, infusion or pill…hmmm🤔
Sponsored By Hello Traders-Jeff Bishop Here! If you’ve been following our updates about MyMD, you know we’ve been focusing primarily on MYMD-1® and its Phase 2 trial as a therapy for delaying aging and prolonging healthy lifespan. To do this, MYMD-1® is...
🤞🙏🤞Dr. Alkon hopeful for an Alzheimer’s breakthrough
Sponsored By Dear Traders- Jeff Bishop here! If you’ve been following our updates you know we’ve been featuring Synaptogenix (SNPX) and its lead therapeutic candidate Bryostatin-1 for the treatment of the disease we all know...
Scientists Are Obsessed with THESE TWO Questions
Sponsored By Greetings Traders, “What causes a person’s body to attack itself?” and “Why is a particular tissue selected as the target?” Although these questions have completely stumped scientists, what happens to the body has not. Autoimmune diseases wreak...
This stock needs to be on your radar, again
Sponsored By See Disclosure Below Take note, Trader! It has been over a week since I talked about MYMD. As you know, I have been bullish on MyMD for some time now. Why should you care about this tiny biotech stock? For starters, I think that anyone 40 years...